Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector, Inc.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. 

Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. 

Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

INmuneBIO

OrbiMed

Polaris Partners

Mission Bay Capital

Section 32 Mission BioCapital

Casdin Capital

Google Ventures

Deerfield Capital Management

Euclidean Capital

Amgen Ventures

Alector

2023 was an exceptional year for Alector. Patients & their families were at the forefront of our minds as we executed on our mission and moved closer to achieving our ambitious vision of making brain disorders history. Below, Alector leaders Arnon Rosenthal and Sara Kenkare-Mitra share their reflections on this year as we head into #2024.

Last week, Alector hosted two R&D webinars for analysts, investors & industry on our targets TREM2 and PGRN and shared the significant progress we have made across our clinical programs. We were joined by esteemed thought leaders in the field who contributed to an invaluable dialog. You can catch up on the conversation at the link below. 

Alector continues to be a pioneer in immuno-neurology, and we are excited about the potential to make a difference in the lives of people with #neurodegenerative diseases. 

https://lnkd.in/eARBjk6

During this season of gratitude, we're reminded how lucky we are to have the opportunity to #giveback to our local community. We partnered with Family Giving Tree once again this holiday season to collect gifts and funds for local families in need. We're inspired by the incredibly valuable work organizations like these do. 🎁

The holidays offer a unique opportunity to remind loved ones how much we care about them through gifts or quality time. Taking care of our brain health becomes increasingly important as we grow older. Check out Alector’s top 6 evidence-based holiday gift ideas for enhancing cognitive reserve and lowering risk of #dementia.

Sources: https://lnkd.in/es7R7PAD

The commitment to advocating for, and caring for, people living with a #neurodegenerative disease does not stop, regardless of the season. This winter, we continue to be in awe of our advocacy group partners and their dedication to patients and their families. Thank you for all you do.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	416K -	3.73M 797.84%	27.68M 641.02%	21.22M 23.33%	21.10M 0.57%	207.09M 881.54%	133.62M 35.48%	97.06M 27.36%
cost of revenue								8.85M -
gross profit	416K -	3.73M 797.84%	27.68M 641.02%	21.22M 23.33%	21.10M 0.57%	207.09M 881.54%	133.62M 35.48%	88.21M 33.98%
selling and marketing expenses
general and administrative expenses	1.87M -	6.50M 247.01%	11.93M 83.52%	35.09M 194.08%	59.40M 69.26%	55.04M 7.35%	61.03M 10.89%	56.69M 7.12%
selling general and administrative expenses	1.87M -	6.50M 247.01%	11.93M 83.52%	35.09M 194.08%	59.40M 69.26%	55.04M 7.35%	61.03M 10.89%	56.69M 7.12%
research and development expenses	13.67M -	29.91M 118.74%	73.03M 144.16%	100.53M 37.65%	156.87M 56.05%	189.41M 20.74%	210.42M 11.09%	192.12M 8.70%
other expenses	22K -	199K 804.55%	5.04M 2,432.66%	9.02M 78.95%	4.95M 45.16%	1.03M 79.15%	7.78M 654.41%	26.56M 241.49%
cost and expenses	15.55M -	36.41M 134.20%	84.97M 133.33%	135.62M 59.62%	216.27M 59.47%	244.44M 13.03%	271.45M 11.05%	248.80M 8.34%
operating expenses	15.55M -	36.41M 134.20%	84.97M 133.33%	135.62M 59.62%	216.27M 59.47%	244.44M 13.03%	271.45M 11.05%	248.80M 8.34%
interest expense							-16.25M -
ebitda	-14.93M -	-32.00M 114.31%	-57.29M 79.03%	-114.40M 99.70%	-195.17M 70.60%	-37.36M 80.86%	-137.83M 268.93%	-142.89M 3.67%
operating income	-15.13M -	-32.68M 115.96%	-57.29M 75.31%	-114.40M 99.70%	-195.17M 70.60%	-37.36M 80.86%	-137.83M 268.93%	-151.74M 10.09%
depreciation and amortization	201K -	680K 238.31%	1.02M 49.85%	5.57M 447.01%	7.26M 30.34%	8.31M 14.45%	8.47M 1.89%	8.85M 4.44%
total other income expenses net	22K -	199K 804.55%	5.04M 2,432.66%	9.02M 78.95%	4.95M 45.16%	1.03M 79.15%	7.78M 654.41%	26.56M 241.49%
income before tax	-15.11M -	-32.48M 114.96%	-52.25M 60.86%	-105.39M 101.70%	-190.23M 80.51%	-36.33M 80.90%	-130.06M 257.99%	-125.18M 3.75%
income tax expense			5.04M -	-5.57M 210.60%	-7.26M 30.34%	-8.31M 14.45%	3.25M 139.13%	5.21M 60.17%
net income	-15.11M -	-32.48M 114.96%	-52.25M 60.86%	-99.81M 91.03%	-182.96M 83.31%	-28.01M 84.69%	-133.31M 375.87%	-130.39M 2.19%
weighted average shs out	51.22M -	51.22M 0%	68.37M 33.46%	61.73M 9.70%	77.76M 25.96%	80.42M 3.42%	82.47M 2.55%	83.73M 1.54%
weighted average shs out dil	51.22M -	51.22M 0%	68.37M 33.46%	61.73M 9.70%	77.76M 25.96%	80.42M 3.42%	82.47M 2.55%	83.73M 1.54%
eps	-0.29 -	-0.63 117.24%	-0.76 20.63%	-1.62 113.16%	-2.35 45.06%	-0.35 85.11%	-1.62 362.86%	-1.56 3.70%
epsdiluted	-0.29 -	-0.63 117.24%	-0.76 20.63%	-1.62 113.16%	-2.35 45.06%	-0.35 85.11%	-1.62 362.86%	-1.56 3.70%

COM:ALECTOR

Alector, Inc.

Last Close

3.76

22/11 21:00

Market Cap

483.85M

Beta: -

Volume Today

715.70K

Avg: -

Preview